CDXS logo

Codexis, Inc. Stock Price

NasdaqGS:CDXS Community·US$229.3m Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author
Create a narrative

CDXS Share Price Performance

US$2.54
-0.58 (-18.59%)
76.9% undervalued intrinsic discount
US$11.00
Fair Value
US$2.54
-0.58 (-18.59%)
76.9% undervalued intrinsic discount
US$11.00
Fair Value
Price US$2.54
AnalystHighTarget US$11.00
AnalystConsensusTarget US$7.08

CDXS Community Narratives

AnalystHighTarget·Updated
Fair Value US$11 76.9% undervalued intrinsic discount

Sustainable Enzyme Engineering Will Power Expanding Biopharma Opportunities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$7.08 64.1% undervalued intrinsic discount

ECO Platform Partnerships Will Transform Pharma Manufacturing

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative

Recent CDXS News & Updates

Codexis Weighs ECO Scale As Cash Runway Tightens

Sep 16

What You Can Learn From Codexis, Inc.'s (NASDAQ:CDXS) P/S

Jul 03
What You Can Learn From Codexis, Inc.'s (NASDAQ:CDXS) P/S

Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 17
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
User avatar

ECO Synthesis Launch In 2025 Will Unlock Pharma Contracts

Transitioning to commercial execution with ECO Synthesis and partnerships enhances revenue growth by securing new contracts and expanding into pharma and biotech segments.

Codexis, Inc. Key Details

US$57.2m

Revenue

US$63.1m

Cost of Revenue

-US$6.0m

Gross Profit

US$59.0m

Other Expenses

-US$65.0m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-0.72
Gross Margin
-10.42%
Net Profit Margin
-113.67%
Debt/Equity Ratio
70.8%

Codexis, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 
View more competitors

Snowflake Analysis

Adequate balance sheet with low risk.

3 Risks
1 Reward
View Full Analysis

About CDXS

Founded
2002
Employees
188
CEO
Stephen Dilly
WebsiteView website
www.codexis.com

Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Market Insight

Header cover image

✨Rare Earths: Tiny Market, Outsized Influence

Richard Bowman avatarRichard Bowman
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Last Week
⚡ Utilities: Defensive Dividends Meet the AI Power Surge

⚡ Utilities: Defensive Dividends Meet the AI Power Surge

U.S. Market Performance

  • 7 Days: 0.9%
  • 3 Months: 8.7%
  • 1 Year: 18.4%
  • Year to Date: 14.8%
The market is up 1.2% over the last week, with the Information Technology sector leading the way, up 2.4%. As for the past 12 months, the market is up 18%. Looking forward, earnings are forecast to grow by 15% annually. Market details ›